Version history

{
  "tags": [
    "CD38",
    "NAD+",
    "senescence",
    "anti-aging",
    "BindCraft",
    "catalytic-inhibition"
  ],
  "text": "A de novo protein binder targeting the CD38 catalytic cleft (hotspot residues C119, K121, W125, F143, E146, D155, L157, Q226 from PDB 2I65, 1.9 Å resolution) is hypothesized to competitively inhibit CD38 NADase/cyclase activity and elevate tissue NAD+ levels in aged tissues, counteracting the NAD+ decline hallmark of aging.",
  "links": {
    "source_papers": [],
    "source_datasets": [
      "PDB:2I65",
      "UniProt:P28907"
    ],
    "supporting_figures": []
  },
  "analysis": "CD38 (UniProt P28907) is the dominant NAD+ consumer in aged tissues. Catalytic cleft hotspot residues C119, K121, D155, D156, L157, D179, C201 were identified from PDB 2I65 (apo, 1.9 Å) and PDB 4XJS (inhibitor-bound, 2.8 Å, quinoline carboxamide). Centroid coordinates locked for BindCraft conditioning: C119(-10.921, 6.311, -9.356), K121(-14.362, 5.x, x.x). Identification strategy: in_silico_KO.",
  "local_id": "claim-cd38-nadsase-inhibition-hypothesis",
  "confidence": "moderate",
  "created_by": "persona-kris-ganjam"
}